This bill adds new statutory sections and amends an existing definitions provision to restrict how prescription drug benefit rules can treat nonopioid pain drugs compared to opioids. It prohibits designating a nonopioid as a nonpreferred drug if any opioid is designated preferred, and it prohibits using prior authorization, step therapy, or other prescription drug utilization management practices that are more restrictive for a nonopioid drug than the least restrictive practice applied to an opioid or narcotic drug. The bill defines key terms including “nonopioid drug,” “prescription drug utilization management,” “prior authorization,” and “step therapy,” and it amends RCW 48.43.400 so those definitions apply to specified related sections. The change creates new regulatory law (new sections added to chapters 41.05, 48.43, 74.09, and 43.70 RCW) and modifies an existing statute (RCW 48.43.400). It is a procedural and regulatory change governing benefit design and utilization management; it does not create a new crime or change criminal penalties in the provided text. The new rules apply to health plans issued or renewed on or after January 1, 2026, and to managed care organizations beginning January 1, 2026. The department named in chapter 43.70 RCW must develop and publish an educational pamphlet about nonopioid alternatives by January 1, 2026. The extracted text does not identify which specific state authority or department is meant by “the authority” referenced in chapter 74.09 RCW or fully show the contents of RCW 48.43.410 and 48.43.420. The provided material also does not include enforcement mechanisms, penalties, or administrative guidance for noncompliance.

If enacted, health plans issued or renewed on or after January 1, 2026 and managed care organizations will no longer be allowed to treat FDA‑approved nonopioid pain drugs as less preferred or subject them to stricter prior authorization or step therapy rules than opioids. In practical terms this will likely make it easier for clinicians to obtain nonopioid medications for patients because carriers and prescription drug management entities must change formularies and utilization-management policies so nonopioids are not disadvantaged, and the state authority responsible for chapter 74.09 RCW must oversee compliance for fee‑for‑service and managed care programs. The parties most affected are employers’ health plans under chapter 41.05 RCW, health plans under chapter 48.43 RCW, managed care organizations and the health carriers and utilization‑management entities that operate prior authorization and step‑therapy programs; they will need to revise policies and operations (which could create administrative work and potential cost shifts) and lose an option to impose tougher controls on nonopioids than on opioids. The department named in the act must also produce an educational pamphlet about nonopioid alternatives by January 1, 2026. The extract does not identify which specific state authority or department is referenced for oversight and does not include enforcement mechanisms, penalties, or detailed implementation guidance.